A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07327229 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: ATG-022
DRUG: pembrolizumab/KEYTRUDA®
DRUG: CAPOX

Sponsor

Antengene Biologics Limited

Collaborators

[object Object]